Member Info for Moneymunch

26-Aug-2020

FINNCAP’S LIFE SCIENCES REPORT INDICATES CELL AND GENE THERAPY SECTOR IS DRIVING THE NEXT WAVE OF INNOVATION IN PHARMA

Breakthrough in delivery for cell and gene therapy products has led to a wave of M&A activity as big pharma aims not to miss out on the ‘future of medicine’

AIM healthcare index at the centre of innovation, has risen 6% YTD compared with the AIM all share, which has declined 7%

‘finnLife 50’ index has also risen 6% in 2020 led by gains in Synairgen (+2,930%), Avacta (+654%), Omega Diagnostics (+322%) and Tiziana Life Sciences (+283%)

London 25 August 2020 – Healthcare companies employing and developing cell and gene therapy (C>) are driving the next wave of innovation in the pharmaceutical industry, leading to increased M&A activity as big pharma aims not to miss out on the ‘future of medicine’. The AIM healthcare index has been at the centre of this innovation, rising 6% YTD compared with the AIM all share, which has declined 7%.

These are the findings of finnCap’s new quarterly Life Sciences sector report, ‘Rude Health’.

Rather than just treating a disease and its symptoms, C> can target the underlying cause of a disease, with long-term benefits and curative potential. C> is now being realised on an applicable level, with many products already approved and the FDA expects to approve 10-20 products a year by 2025.

The financials of the sector are reflective of this rapid progress. In 2018, the market value of C> was $536 million - $1.07 billion; but by 2026 it is set to have a valuation of up to$35.4 billion. Given the high proportion of start-ups in the sector, M&A activity is on the rise, as evidenced by the $3 billion Astellas spent in January 2020 to acquire Audentes Therapeutics, specialists in genetics medicines.

In 2014/2015, M&A activity in the sector was $5 billion; by 2018/2019 it had surged 880% to $49 billion. Much of this is driven by big pharma firms not wanting to fall behind their smaller, more versatile competition, as they did with monoclonal antibody technology. Consequently, they have engaged with M&A to speed up and enhance their own R&D efforts.

The report notes that innovators in C> will be well placed to take part in the land grab that will follow as a result of continued advancements in the sector, and highlights now as a good time for investors and pharmaceutical companies to become involved as the sector is rapidly maturing past its high potential research and development stage – with an established pipeline of therapies already being developed.

Looks like they want to hoover UP every single share on the cheap before they make the Major announcement imho.....we had the massive share transfers and we've had the constant share accumulation of every single share sold on a daily basis for weeks and months....mine are held very tightly indeed.....Gla ;-))))

Looks like the sp is going to head to kingalf's recent prediction of 15.5p...ho ho ho ho ho....in anticipation of potential transformational imminent news....Gla holders.....Evgen could be ready to deliver at long last...On and UP!!!

Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2S donors in COVID-19 therapy

First published: 11 August 2020

The COVID-19 pandemic caused by SARS-Cov-2 demands rapid, safe and effective therapeutic options. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H2S) has emerged as modulator of several biological functions and its deficiency has been associated with different disorders. Therefore, many H2S-releasing agents have been developed as potential therapeutic tools for diseases related with impaired H2S production and/or activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H2S in modulating the inflammatory response and pro-inflammatory cytokine cascade is well recognized, and the usefulness of some H2S-donors for the treatment of acute lung inflammation has been reported. Recent data is elucidating several mechanisms of action, which may account for antiviral effects of H2S. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H2S levels and severity of COVID-19. Therefore, repurposing of H2S-releasing drugs may be a potential therapeutic opportunity for treatment of COVID-19.

..................................

5 CONCLUSIONS

The severity of COVID-19 pandemic is mainly based on two relevant aspects: high degree of contagiousness and high frequency of massive inflammatory reactions, which lead to serious and life-threatening disease outcomes. In this perspective, the pathophysiological role of the gasotransmitter H2S provides opportunities for additional investigation. This endogenous mediator can modulate the inflammatory response in a complex regulation of the cytokine cascade. Moreover, preliminary studies point to a role of H2S in regulating the host response to viral infections (Yang, 2020). Such evidence provides a strong case for the potential antiviral benefits offered by different classes and chemotypes of H2S donor molecules as therapeutic agents, as recently proposed also by other pioneering hypotheses (Evgen'ev & Frenkel, 2020; Yang, 2020). Several compounds already in clinical development for other therapeutic indications, such as SG1002 or sulforaphane, can be viewed as potential high-value candidates for rapid repurposing for antiviral therapy against COVID-19.

https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15230

Press Release
Covid-19 brings research switch for Ashley

Published on 25 June 2020

When Ashley Giam left Singapore for the UK, she could not have imagined that the move would lead to her working on potential treatments for the deadliest pandemic the world has seen for a century.

The projects Ashley has worked on include STOP-COVID19, the clinical trial of brensocatib, an anti-inflammatory drug that is hoped may help to prevent the worst ravages of the novel coronavirus. Ashley is also now playing a leading role in the study of another new anti-inflammatory drug called SFX-01. This medication reduces lung damage through the pathway that Ashley has been studying during her PhD. She is now working in the laboratory to understand whether this medicine could reduce the number of coronavirus patients requiring mechanical ventilation and, ultimately, cutting death rates from the disease.

https://www.dundee.ac.uk/stories/covid-19-brings-research-switch-ashley

Prof James Chalmers ( Lead Investigator for SFX-01's Covid-19 patinet trials ) has been working over time if you checkout his twitter, publishing phase 2 results for Bronchitis and confirming first patients enrolled in STOP-COVID19 trial of Brensocatib and even praises a research student who is focussed on SFX-01......surely it can't be too much longer for Covid-19 patient trials ....Gla ;-)

Pinned Tweet
James D Chalmers
@ProfJDChalmers
·
18h
We are delighted to publish the final results of the WILLOW trial of DPP1 inhibition in bronchiectasis in the @NEJM
- thanks to all patients and investigators that made this possible
Results show a new anti-inflammatory approach may reduce exacerbations
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM
Original Article from The New England Journal of Medicine — Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
nejm.org
James D Chalmers
@ProfJDChalmers
·
12m
Important news that @nhsfife
have randomized their first patient into the STOP-COVID19 trial of Brensocatib
The trial is active across Scotland - great that Scotland is working together to find new treatments for #COVID19 @NHSResearchScot
@TASC_TCTU

hxxps://stop-covid19.org.uk
Image
James D Chalmers
@ProfJDChalmers
·
15m
Great recognition of Yan Hui Giam, who has changed direction and now working incredibly hard on COVID-19 trials during the pandemic @dundeeuni
@TASC_Research
@NHSResearchScot

Scientists working long hours to deliver priority research are unsung heroes @MereteLong
@KeirHolly
Quote Tweet
Study UK
@StudyUKBritish
· 2h
Following the outbreak of Covid-19, Singaporean student, Giam Yan Hui, changed her research focus during her PhD at @dundeeuni. She is now working on anti-inflammatory drugs that could treat or reduce lung inflammation in Covid-19 patients. Learn more
Down pointing backhand index

https://twitter.com/ProfJDChalmers?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Lol...you clueless sad and bitter twit.....I first highlighted MTFB at sub 0.02p and it hit 1.49p and plenty made plenty and still remains up well over 100% since i first highlighted the potential upside, as they still await news of a potential RTO.....in the meantime , bring on your 15.5p prediction here....Ker-Ching!!! :-)

Deepest Surrey you sap....15.5p ....bring it on you confused dimwit...;-)

Ps potentially the sp could go much higher, infact multiples of 15.5p with the right news...Gla Holders Tick Tock Booooooom!!! :-)

Not only a dimwit, but a very confused dimwit who now reckons it's a good opportunity to buy EVG before the sp heads back to 15.5p.....ha ha ha ha....Fill Ya boots according to king elf.....:-(

Kingalf

Posted in: EVG

Posts: 22

Price: 12.225

No Opinion

RE: Top up time ?05 Sep 2020 15:00

Ignore MM, he is clearly talking out of his a__e
Should test 11p in the next few sessions, which should be a good buying opportunity for a move back up to around 15.5p.

I better post this again then for genuine pi's and are considering Evgen's prospects and potential if this is what you're trying to drown out...ho ho ho ...Gla holders...Potential Transformational news has never been closer....and looks like the desperate dimwit is determined to deter investors....ha ha ha :-)

Strategic Investor - JVToday 17:42

 0

Blackstone recently bought into Reata for $350m to advance their Nrf2 activatior pipeline, and so plenty of reasons why Blackstone or another would be interested in Evgen and SFX-01's panacea potential, including SFX-01's non pharma potential that Blackstone now appears to be interested in buying Takeda consumer healthcare business...and surely not too much longer to find out, and still every chance that a strategic investor JV commercial partner is waiting in the wings which would explain the time it's taking to announce a new CEO...Gla ;-)

Blackstone Group Inc. (NYSE: BX) is buying Takeda Pharmaceutical Co.'s Japanese consumer healthcare business for 242 billion yen ($2.3 billion). The PE firm plans to take the over-the-counter medication unit public in about five years, reports Bloomberg News. For the drugmaker, the sale represents another piece of its plan to dispose $10 billion in assets after its $62 billion mega-acquisition of Shire Plc last year. Blackstone aims to invest 50 billion yen into the business, with a goal of exiting the investment in about five years by taking the company public, says Atsuhiko Sakamoto, a senior managing director at Blackstone, in an interview with Bloomberg. Blackstone is flush with cash as investors continue to bet big on the firm amid the uncertainty caused by the Covid-19 pandemic. Many of the firm’s recent investments have been in growth companies and businesses likely to benefit from shifts in consumer behavior. It has spent more than $1 billion this year investing in drugs that target high cholesterol, kidney disease in children and devices for diabetes patients. Read the full story by Bloomberg: Blackstone buys Takeda's consumer healthcare unit for $2.3 billion.

Private equity investors aren’t the only ones announcing healthcare deals. Strategic buyers are rapidly snatching up targets focused on developers targeting a wide range of diseases, including the coronavirus, but not limited to it. Johnson & Johnson agreed to buy Momenta Pharmaceuticals Inc. for about $6.5 billion to expand in treatments for autoimmune diseases. Sanofi recently announced it is buying biotech company Principia Biopharma Inc., which develops treatments for multiple sclerosis and a range of autoimmune disorders, for $3.4 billion, as the French drugmaker pivots toward innovative therapies to spur growth. And AstraZeneca plc is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic. The U.K. drugmaker paying as much as $6 billion to buy into Daiichi Sankyo Co.’s promising medicine for lung and breast cancer, the drug

Lol...you desperate clueless sap.....I've been highlighting Evgens prospects since 7p you idiot ....potential Transformational news has never been closer....and you're going to disappear back under your stone when it does...ha ha ha ....:-)

 0

Blackstone recently bought into Reata for $350m to advance their Nrf2 activatior pipeline, and so plenty of reasons why Blackstone or another would be interested in Evgen and SFX-01's panacea potential, including SFX-01's non pharma potential that Blackstone now appears to be interested in buying Takeda consumer healthcare business...and surely not too much longer to find out, and still every chance that a strategic investor JV commercial partner is waiting in the wings which would explain the time it's taking to announce a new CEO...Gla ;-)

Blackstone Group Inc. (NYSE: BX) is buying Takeda Pharmaceutical Co.'s Japanese consumer healthcare business for 242 billion yen ($2.3 billion). The PE firm plans to take the over-the-counter medication unit public in about five years, reports Bloomberg News. For the drugmaker, the sale represents another piece of its plan to dispose $10 billion in assets after its $62 billion mega-acquisition of Shire Plc last year. Blackstone aims to invest 50 billion yen into the business, with a goal of exiting the investment in about five years by taking the company public, says Atsuhiko Sakamoto, a senior managing director at Blackstone, in an interview with Bloomberg. Blackstone is flush with cash as investors continue to bet big on the firm amid the uncertainty caused by the Covid-19 pandemic. Many of the firm’s recent investments have been in growth companies and businesses likely to benefit from shifts in consumer behavior. It has spent more than $1 billion this year investing in drugs that target high cholesterol, kidney disease in children and devices for diabetes patients. Read the full story by Bloomberg: Blackstone buys Takeda's consumer healthcare unit for $2.3 billion.

Private equity investors aren’t the only ones announcing healthcare deals. Strategic buyers are rapidly snatching up targets focused on developers targeting a wide range of diseases, including the coronavirus, but not limited to it. Johnson & Johnson agreed to buy Momenta Pharmaceuticals Inc. for about $6.5 billion to expand in treatments for autoimmune diseases. Sanofi recently announced it is buying biotech company Principia Biopharma Inc., which develops treatments for multiple sclerosis and a range of autoimmune disorders, for $3.4 billion, as the French drugmaker pivots toward innovative therapies to spur growth. And AstraZeneca plc is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic. The U.K. drugmaker paying as much as $6 billion to buy into Daiichi Sankyo Co.’s promising medicine for lung and breast cancer, the drugmakers’ second potential blockbuster oncology deal in two years. Read the full story: Covid pandemic fuels healthcare M&A, with recent deals from Johnson & Johnson, Sanofi, AstraZeneca and former KKR exec Jim Montazee.

Lol.......Brain of Britain....Warren Buffet sits on a position that he thinks will has massive UPside potential.... my substantial holding here sits at an average of 11p and i'm not interested in 20 to 30% returns....Gla Holders Tick Tock Boom!!! ;-)

Lol...kingalf the Evgen share basher is predicting 15.5p....ha ha ha ....bring it on...ho ho ho ho :-)

Ps what on earth will radar have to say about it ;-))))

The smart Money is accumulating......massive Upside imminent....Gla ;-)

Reata was mentioned in the Final Results when their market cap was $5 BILLION , they lost over $1 billion last month when they announced delays and possible further trials before FDA approval for one of their Nrf2 targets , and so the comaparrison in value is staggering and highlights Evgen's undoubted upside potential, and perhaps Reata could very interested in SFX-01....Gla ;-)

15/6/20

Barry Clare, Executive Chairman of Evgen Pharma, said: "We move forward with the confidence that the value of SFX-01 as a potential drug that is active against the two key pathways of Nrf2 and STAT3 will become increasingly clear. These pathways are of significance in a range of diseases including cancer, autism and those where oxidative stress is a factor. We therefore believe that the fundamentals are in place to underpin sustainable share price growth and deliver the undoubted potential of SFX-01. On behalf of myself and the Board, I would like to thank our shareholders for their continued support and we look forward to updating the market with positive news in the coming year."

...............

There remains a strong rationale for clinically testing SFX-01 in any condition that is mechanistically linked to Nrf2, as evidenced by the recent positive developments at Reata (NASDAQ: RETA). Reata is developing Nrf2 activators based on triterpenoids and with positive top-line results in pivotal trials in Friedriech's Ataxia and Alport Syndrome has a current market capitalisation of circa US$5bn. This illustrates that the fundamentals of Nrf2 activation as a therapeutic strategy are sound and SFX-01 is a potent and well tolerated Nrf2 activator; on this basis we advance with confidence in SFX-01.

..................

Evgen has exclusive rights to the only technology (Sulforadex(R)) proven to synthesise this very unstable molecule in a stabilised composition that will satisfy regulatory and medicinal needs for a pharmaceutical and that can be used as a therapeutic.

Lol radar, you desperate cluless share basher, Reata's market cap is $3.39 BILLION and Evgen's is £17m , Reata's two lead Nrf2 activators aren't that much more clinically advanced then Evgen's pipeline and unlike Reata's compounds, SFX-01 already has a confirmed safety profile....the gulf in valuation and potential upside from Evgen's m/c must regisiter even with a dimwit like you....ha ha h ha .....Gla Holders.....BIG news fast approaching!!! ;-)

Looks like Reata are expecting good new on their Nrf2 activator...Gla ;-)

September 03, 2020 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich’s Ataxia at the American Academy of Neurology

PLANO, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the forthcoming presentation of efficacy and safety results from the pivotal MOXIe Part 2 study, a randomized, double-blind, placebo-controlled trial of omaveloxolone in Friedreich’s ataxia.

The presentation will take place on September 24, 2020 as part of the 2020 Emerging Science presentations hosted by the American Academy of Neurology (AAN). David Lynch, M.D., Ph.D., will present the data. Dr. Lynch is an attending physician at the Children’s Hospital of Philadelphia (CHOP), professor of neurology at the Perelman School of Medicine at the University of Pennsylvania, and the principal investigator of the MOXIe study.

http://www.globenewswire.com/news-release/2020/09/03/2088310/0/en/Reata-Announces-the-Presentation-of-the-Pivotal-MOXIe-Part-2-Study-of-Omaveloxolone-in-Friedreich-s-Ataxia-at-the-American-Academy-of-Neurology.html

The 350k trade is from yesterday, Non protected portfolio, Single protected transaction - which is a share trade between institutions.....the share transfer / accummulation continues.....C'mon Evgen , it's about time we had some news!!! ;-)

Perfectly poised and primed!!! ;-)))